Targets › GCG
2 programs from 2 companies in 23 trials: 12 Phase 1, 10 Phase 3, 1 Phase 2; Metabolic and endocrine, Oncology, Cardiovascular; next expected readout Jan 2027.
[Glucagon]: Plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. (UniProt, P01275)
Open in Phaseline: the race on GCG, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novo Nordisk | Cagrilintide B Dual GLP-1/glucagon receptor agonist | GLP1R, GCG, CALCR | Phase 3 | Obesity; Overweight; Cardiovascular Disease; Diabetes Mellitus, Type 2 | Jan 2027 |
| AstraZeneca | AZD6234 in combination with AZD9550 Dual GCG and GLP-1 receptor agonist | GCG, GLP1R | Phase 2 | Obesity/Overweight; Healthy Participants; Overweight and Obesity; Hepatic Impairment | Jan 2027 |
Obesity (11) Overweight (5) Healthy Participants (2) Obesity/Overweight (1) Overweight and Obesity (1) Hepatic Impairment (1) Cardiovascular Disease (1) Diabetes Mellitus, Type 2 (1)
small molecule (1), protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.